News
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
October 15, 2024
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
Press
Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
BioLoomics’ goal is to make a degrader from an antibody in one month
Press
BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
Our mission is to make safer, more effective cancer therapeutics.
News
Pre-Seed Extension
BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021..
News
OEDIT Grant Award
The Colorado OEDIT provides funding opportunities to small businesses in fourteen industries...
News
BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform
We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round...
Press